Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2... more
Product information "13,14-dihydro-15-keto Prostaglandin E2"
13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2 (Cay-14010) and the primary PGE2 metabolite in plasma. It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Delta13 reductase. Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 µM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 µM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).Formal Name: (5Z,11alpha)-11-hydroxy-9,15-dioxo-prost-5-en-1-oic acid. CAS Number: 363-23-5. Synonyms: 13,14-dihydro-15-keto PGE2, 13,14-dihydro-oxo-PGE2, PGEM. Molecular Formula: C20H32O5. Formula Weight: 352.5. Purity: >95%. Formulation: (Request formulation change), A solution in methyl acetate. Solubility: DMF: >100 mg/ml, DMSO: >100 mg/ml, Ethanol: >100 mg/ml, PBS (pH 7.2): >5 mg/ml. SMILES: O=C1[C@H](C/C=C\CCCC(O)=O)[C@@H](CCC(CCCCC)=O)[C@H](O)C1. InChi Code: InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-17,19,23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,19-/m1/s1. InChi Key: CUJMXIQZWPZMNQ-XYYGWQPLSA-N.
Keywords: | 13,14-dihydro-15-keto PGE2, 9,15-dioxo-11alpha-hydroxy-prost-5Z-en-1-oic acid |
Supplier: | Cayman Chemical |
Supplier-Nr: | 14650 |
Properties
Application: | Bioactive lipid assays |
MW: | 352.5 D |
Formula: | C20H32O5 |
Purity: | >95% |
Format: | Solution |
Database Information
CAS : | 363-23-5| Matching products |
KEGG ID : | K00069 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | -20°C (International: -20°C) |
Signal Word: | Danger |
GHS Hazard Pictograms: |
![]() ![]() |
H Phrases: | H225, H319, H336, H303, H333, H316 |
P Phrases: | P210, P240, P241, P242, P243, P261, P264, P271, P280, P312, P303+P361+P353, P304+P340, P305+P351+P338, P332+P313, P337+P313, P370+P378, P405, P403+P233, P403+P235, P501 |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed